False Negativity of Targeted Axillary Dissection in Breast Cancer

False Negativity of Targeted Axillary Dissection in Breast Cancer

Introduction: Targeted axillary dissection (TAD) has been proposed as an alternative method for the staging of patients with node-positive breast cancer who undergo neoadjuvant chemotherapy. However, not much is known yet about the false-negative rate (FNR) of the method and the subsequent risk of u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast care (Basel, Switzerland) Switzerland), 2021-10, Vol.16 (5), p.532-538
Hauptverfasser: Kirkilesis, George, Constantinidou, Anastasia, Kontos, Michalis
Format: Artikel
Sprache:eng
Schlagworte:
Systematic Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 538
container_issue 5
container_start_page 532
container_title Breast care (Basel, Switzerland)
container_volume 16
creator Kirkilesis, George
Constantinidou, Anastasia
Kontos, Michalis
description Introduction: Targeted axillary dissection (TAD) has been proposed as an alternative method for the staging of patients with node-positive breast cancer who undergo neoadjuvant chemotherapy. However, not much is known yet about the false-negative rate (FNR) of the method and the subsequent risk of underestimation of residual axillary disease. Methods: This study reviews published articles with calculations of false negativity of TAD and potential factors that may influence it. Results: The FNR of TAD is usually reported as being
doi_str_mv 10.1159/000513037
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34720813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2591221635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-4264046f4c3ddaa0d618939b1563889968497cc4e5148846fbae02d4b670cbdc3</originalsourceid><addsrcrecordid>eNptkM9LwzAUx4Mobk4P3kUCXvRQTZofTS_CVp0KQ0HmOaRpOqNbO5NuuP_elm5FwdN78D7v-77vC8ApRtcYs_gGIcQwQSTaA33MOQ6IQGx_10cx7oEj7z8QopxE_BD0CI1CJDDpg-FYzb2Bz2amKru21QaWOZwqNzOVyeDw287nym3gnfXe6MqWBbQFHDmjfAUTVWjjjsFB3micbOsAvI3vp8ljMHl5eEqGk0DTkFYBDTmt7-dUkyxTCmUci5jEKWacCBHHXNA40poahqkQNZgqg8KMpjxCOs00GYDbVne5Shcm06aonJrLpbOL2qEslZV_J4V9l7NyLQWjJBSsFrjcCrjya2V8JRfWa1M_WJhy5WXIYhyGmJMGvWpR7Urvncm7MxjJJnLZRV6z5799deQu4xo4a4HPJlbXAd3-xb_j0WvSEnKZ5eQH07yP5Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2591221635</pqid></control><display><type>article</type><title>False Negativity of Targeted Axillary Dissection in Breast Cancer</title><source>Karger Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kirkilesis, George ; Constantinidou, Anastasia ; Kontos, Michalis</creator><creatorcontrib>Kirkilesis, George ; Constantinidou, Anastasia ; Kontos, Michalis</creatorcontrib><description>Introduction: Targeted axillary dissection (TAD) has been proposed as an alternative method for the staging of patients with node-positive breast cancer who undergo neoadjuvant chemotherapy. However, not much is known yet about the false-negative rate (FNR) of the method and the subsequent risk of underestimation of residual axillary disease. Methods: This study reviews published articles with calculations of false negativity of TAD and potential factors that may influence it. Results: The FNR of TAD is usually reported as being &lt;10%, but this calculation is usually based on small study populations. Lower FNR is a common finding along with lower N status, while not enough data are available yet for greater axillary involvement. When a marked node is revealed to be a sentinel lymph node (SLN) at surgery after neoadjuvant chemotherapy (NAC), this seems to be another factor that contributes to reliable TAD. With regard to the methods used to mark the positive node before chemotherapy and retrieval at surgery, there is no clear advantage of one over the other. The availability of relevant resources, the costs, and local legislation must all be taken into account for the selection of the optimal strategy. Conclusion: Although still in its early days, the FNR of TAD can be low, at least in patients with relatively little axillary involvement and when the marked node is the SLN. All reported methods of lymph node marking seem reliable.</description><identifier>ISSN: 1661-3791</identifier><identifier>EISSN: 1661-3805</identifier><identifier>DOI: 10.1159/000513037</identifier><identifier>PMID: 34720813</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Systematic Review</subject><ispartof>Breast care (Basel, Switzerland), 2021-10, Vol.16 (5), p.532-538</ispartof><rights>2021 S. Karger AG, Basel</rights><rights>Copyright © 2021 by S. Karger AG, Basel.</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-4264046f4c3ddaa0d618939b1563889968497cc4e5148846fbae02d4b670cbdc3</citedby><cites>FETCH-LOGICAL-c424t-4264046f4c3ddaa0d618939b1563889968497cc4e5148846fbae02d4b670cbdc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543285/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543285/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,2429,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34720813$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kirkilesis, George</creatorcontrib><creatorcontrib>Constantinidou, Anastasia</creatorcontrib><creatorcontrib>Kontos, Michalis</creatorcontrib><title>False Negativity of Targeted Axillary Dissection in Breast Cancer</title><title>Breast care (Basel, Switzerland)</title><addtitle>Breast Care</addtitle><description>Introduction: Targeted axillary dissection (TAD) has been proposed as an alternative method for the staging of patients with node-positive breast cancer who undergo neoadjuvant chemotherapy. However, not much is known yet about the false-negative rate (FNR) of the method and the subsequent risk of underestimation of residual axillary disease. Methods: This study reviews published articles with calculations of false negativity of TAD and potential factors that may influence it. Results: The FNR of TAD is usually reported as being &lt;10%, but this calculation is usually based on small study populations. Lower FNR is a common finding along with lower N status, while not enough data are available yet for greater axillary involvement. When a marked node is revealed to be a sentinel lymph node (SLN) at surgery after neoadjuvant chemotherapy (NAC), this seems to be another factor that contributes to reliable TAD. With regard to the methods used to mark the positive node before chemotherapy and retrieval at surgery, there is no clear advantage of one over the other. The availability of relevant resources, the costs, and local legislation must all be taken into account for the selection of the optimal strategy. Conclusion: Although still in its early days, the FNR of TAD can be low, at least in patients with relatively little axillary involvement and when the marked node is the SLN. All reported methods of lymph node marking seem reliable.</description><subject>Systematic Review</subject><issn>1661-3791</issn><issn>1661-3805</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNptkM9LwzAUx4Mobk4P3kUCXvRQTZofTS_CVp0KQ0HmOaRpOqNbO5NuuP_elm5FwdN78D7v-77vC8ApRtcYs_gGIcQwQSTaA33MOQ6IQGx_10cx7oEj7z8QopxE_BD0CI1CJDDpg-FYzb2Bz2amKru21QaWOZwqNzOVyeDw287nym3gnfXe6MqWBbQFHDmjfAUTVWjjjsFB3micbOsAvI3vp8ljMHl5eEqGk0DTkFYBDTmt7-dUkyxTCmUci5jEKWacCBHHXNA40poahqkQNZgqg8KMpjxCOs00GYDbVne5Shcm06aonJrLpbOL2qEslZV_J4V9l7NyLQWjJBSsFrjcCrjya2V8JRfWa1M_WJhy5WXIYhyGmJMGvWpR7Urvncm7MxjJJnLZRV6z5799deQu4xo4a4HPJlbXAd3-xb_j0WvSEnKZ5eQH07yP5Q</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Kirkilesis, George</creator><creator>Constantinidou, Anastasia</creator><creator>Kontos, Michalis</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211001</creationdate><title>False Negativity of Targeted Axillary Dissection in Breast Cancer</title><author>Kirkilesis, George ; Constantinidou, Anastasia ; Kontos, Michalis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-4264046f4c3ddaa0d618939b1563889968497cc4e5148846fbae02d4b670cbdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Systematic Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kirkilesis, George</creatorcontrib><creatorcontrib>Constantinidou, Anastasia</creatorcontrib><creatorcontrib>Kontos, Michalis</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast care (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kirkilesis, George</au><au>Constantinidou, Anastasia</au><au>Kontos, Michalis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>False Negativity of Targeted Axillary Dissection in Breast Cancer</atitle><jtitle>Breast care (Basel, Switzerland)</jtitle><addtitle>Breast Care</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>16</volume><issue>5</issue><spage>532</spage><epage>538</epage><pages>532-538</pages><issn>1661-3791</issn><eissn>1661-3805</eissn><abstract>Introduction: Targeted axillary dissection (TAD) has been proposed as an alternative method for the staging of patients with node-positive breast cancer who undergo neoadjuvant chemotherapy. However, not much is known yet about the false-negative rate (FNR) of the method and the subsequent risk of underestimation of residual axillary disease. Methods: This study reviews published articles with calculations of false negativity of TAD and potential factors that may influence it. Results: The FNR of TAD is usually reported as being &lt;10%, but this calculation is usually based on small study populations. Lower FNR is a common finding along with lower N status, while not enough data are available yet for greater axillary involvement. When a marked node is revealed to be a sentinel lymph node (SLN) at surgery after neoadjuvant chemotherapy (NAC), this seems to be another factor that contributes to reliable TAD. With regard to the methods used to mark the positive node before chemotherapy and retrieval at surgery, there is no clear advantage of one over the other. The availability of relevant resources, the costs, and local legislation must all be taken into account for the selection of the optimal strategy. Conclusion: Although still in its early days, the FNR of TAD can be low, at least in patients with relatively little axillary involvement and when the marked node is the SLN. All reported methods of lymph node marking seem reliable.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>34720813</pmid><doi>10.1159/000513037</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1661-3791
ispartof Breast care (Basel, Switzerland), 2021-10, Vol.16 (5), p.532-538
issn 1661-3791
1661-3805
language eng
recordid cdi_pubmed_primary_34720813
source Karger Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Systematic Review
title False Negativity of Targeted Axillary Dissection in Breast Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A31%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=False%20Negativity%20of%20Targeted%20Axillary%20Dissection%20in%20Breast%20Cancer&rft.jtitle=Breast%20care%20(Basel,%20Switzerland)&rft.au=Kirkilesis,%20George&rft.date=2021-10-01&rft.volume=16&rft.issue=5&rft.spage=532&rft.epage=538&rft.pages=532-538&rft.issn=1661-3791&rft.eissn=1661-3805&rft_id=info:doi/10.1159/000513037&rft_dat=%3Cproquest_pubme%3E2591221635%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2591221635&rft_id=info:pmid/34720813&rfr_iscdi=true